Description:
The King’s College Hospital NHS Foundation Trust ‘Diabetes and Liver Disease: Time to think in NAFLD’ ECHO Programme is a clinically based educational program designed to improve the knowledge related to diabetes and liver disease.
Through focused presentations and multispeciality case study discussions, the ECHO methodology will facilitate learning, improve communication and strive to simplify patient pathways between primary, secondary and tertiary care sector.
Sessions will include variety of topics within the field of ‘Diabetes and Liver disease’, and the sessions will deliver clinically based teaching with an update on current best practices resulting in increased confidence for all attendees in managing patients with Diabetes and NAFLD.
Each session will last for 60 minutes and it will include a 20 minute teaching , 20 minute case study presentation and a 20 minute discussion related to the topic explored in each session.
Through focused presentations and multispeciality case study discussions, the ECHO methodology will facilitate learning, improve communication and strive to simplify patient pathways between primary, secondary and tertiary care sector.
Sessions will include variety of topics within the field of ‘Diabetes and Liver disease’, and the sessions will deliver clinically based teaching with an update on current best practices resulting in increased confidence for all attendees in managing patients with Diabetes and NAFLD.
Each session will last for 60 minutes and it will include a 20 minute teaching , 20 minute case study presentation and a 20 minute discussion related to the topic explored in each session.
‘Diabetes and Liver Disease: time to think in Non-Alchoholic Fatty Liver Disease (NAFLD)’ ECHO Programme:
28 February 2023 (12:30 - 13:30) - NAFLD & Metabolic Associated Fatty Liver Disease (MAFLD): concept/diagnosis, risk factors & physiopathology.
17 April 2023 (12:30 - 13:30) - Non-invasive biomarker of fibrosis detection: when and where to use.
12 July 2023 (12:30 - 13:30) - Clinical implication and general management.
31 October 2023 (12:30 - 13:30) - Pharmacological treatment for NAFLD.
TBC - January 2024 - Cardiovascular risk with NAFLD.
TBC - January 2024 - Cardiovascular risk with NAFLD.
Each ECHO session will include
· Presentation and a discussion regarding a topic
· Case presentations (NB: these will be anonymised to ensure GDPR)
· Q&A discussion
Research has shown that participation in ECHO sessions leads to:
· More appropriate diagnosis and treatment plans and interventions
· Higher patient satisfaction
· Better linkage into secondary care
· Presentation and a discussion regarding a topic
· Case presentations (NB: these will be anonymised to ensure GDPR)
· Q&A discussion
Research has shown that participation in ECHO sessions leads to:
· More appropriate diagnosis and treatment plans and interventions
· Higher patient satisfaction
· Better linkage into secondary care
What we ask from you:
· Complete registration, GDPR and evaluation forms (Once registered you will receive all updates and links to new sessions as the programme progresses)
· Provide cases to present and discuss
· Your support!
· Complete registration, GDPR and evaluation forms (Once registered you will receive all updates and links to new sessions as the programme progresses)
· Provide cases to present and discuss
· Your support!
